C1 esterase inhibitor – Communicable Diseases Research

Impaired Kallikrein-Kinin System in COVID-19 Patients’ Severity

Observational Study

Published on 2022-06-222022-10-05
Journal: Frontiers in Immunology [Category] 임상,

Sustained inflammation, coagulation activation and elevated endothelin-1 levels without macrovascular dysfunction at 3 months after COVID-19

Research article

Published on 2022-01-012022-10-05
Journal: Thrombosis research [Category] SARS, 바이오마커,

[키워드] Activation acute COVID-19 acute phase Alpha 1 antitrypsin baseline C1 esterase inhibitor C1inhC1 esterase inhibitor CARCarotid Artery Reactivity Cardiovascular health carotid Carotid Artery Reactivity caused CIconfidence interval Coagulation Cohort cohort study complexes Concentration conducted confidence interval Contact Control controls Coronavirus disease 2019 COVID-19 COVID-19 pandemic COVID-19coronavirus disease 2019 cytokine level dysfunction Effect elevated ELISAEnzyme-linked immunosorbent assay Endothelial cell Endothelial dysfunction Endothelin-1 enzyme-linked immunosorbent assay ET-1Endothelin-1 Evidence Factor FFactor Follow-up highlight IL-6 ILInterleukin Inflammation Inflammatory cytokine information interleukin Kallikrein material NLRP3Nod-like receptor family pyrin domain containing 3 Nod-like receptor family pyrin domain containing 3 not differ Patient PCRpolymerase chain reaction PKaKallikrein polymerase chain reaction Prevalence Propensity score propensity score matching PSMPropensity Score Matching RDRisk Difference recovered patients Result risk difference SARS-CoV-2 SARS-CoV-2severe acute respiratory syndrome coronavirus 2 SDStandard deviation severe acute respiratory syndrome coronavirus 2 significantly higher SMDStandardized Mean Differences Standard deviation Standardized Mean Differences subject sustained TATThrombin:Antithrombin the WHO Thrombin:Antithrombin thrombosis vascular inflammation Von Willebrand Factor:Antigen VWF:AgVon Willebrand Factor:Antigen were measured WHOWorld Health Organization World Health Organization α1ATalpha 1 antitrypsin
[DOI] 10.1016/j.thromres.2021.11.027 [Article Type] Research article

Functional Activity of the Complement System in Hospitalized COVID-19 Patients: A Prospective Cohort Study

Observational Study

Published on 2021-10-282022-10-04
Journal: Frontiers in Immunology [Category] MERS, SARS, 임상,

[키워드] 95% CI Activation activity acute lung injury acute phase Admission Alternative pathway Analysis autopsy studies C1 esterase inhibitor collected complement complement system Concentration confounding factors correlated COVID-19 COVID-19 patient Critically ill death Disease progression disease severities disease severity Factor ficolin-3 Follow-up hospitalized COVID-19 patient hospitalized patient ICU admission implicated in vitro in vivo In-hospital death Inflammation Inflammatory marker IQR lectin pathway male mannose-binding lectin mechanical ventilation median multiple comorbidities no significant difference occurred Pathogenesis pathway Patient PCR-confirmed Primary outcome progression Prospective prospective observational study Protein reduced required Result resulting ROC Curve SARS-CoV-2 SARS-COV-2 infection serum sample severe COVID-19 severe disease significantly significantly lower single-center System the patient threshold Ventilation
[DOI] 10.3389/fimmu.2021.765330 PMC 바로가기 [Article Type] Observational Study

Protease inhibitor plasma concentrations associate with COVID-19 infection

Short Communication

Published on 2021-07-072022-10-29
Journal: Oxford Open Immunology [Category] COVID-19,

[키워드] adjusted Anti-inflammatory assays C-reactive protein C1 esterase inhibitor Cohort collected Concentration Control controls coronavirus coronavirus disease correlated Course COVID-19 COVID-19 diagnosis COVID-19 severity demonstrated determine diagnostic dialysis Haemodialysis healthy controls immunoassay Infection inflammatory pathways inhibitor Innate immunity ITIH4 median multiple comparisons Patient patients with COVID-19 patients without COVID-19 plasma plasma concentration Protease inhibitor protease inhibitors quantified repeated measure Result severity of COVID-19 Swab the disease was tested with COVID-19
[DOI] 10.1093/oxfimm/iqab014 PMC 바로가기 [Article Type] Short Communication

Evaluation of the efficacy and safety of icatibant and C1 esterase/kallikrein inhibitor in severe COVID-19: study protocol for a three-armed randomized controlled trial

중증 코로나19 환자에서 이카티반트 및 C1 에스테라제/칼리크레인 억제제의 효능 및 안전성 평가: 3군 무작위 대조 시험 연구 프로토콜

Study Protocol

Published on 2021-01-202022-09-10
Journal: Trials [Category] 비임상, 임상,

[키워드] accumulation ACE inhibitor ACE inhibitors ACE2 angiotensin Angiotensin-converting enzyme angiotensin-converting enzyme 2 animal models anti-inflammatory agents antibiotic antithrombotic therapy assigned binding bradykinin breath C1 esterase inhibitor cause Cell clinical clinical trial clinical trials cough COVID-19 Degradation dependent on driving Efficacy and safety eligible patient expressed Icatibant inactivation include Inflammatory inhibitor intravenously invasive ventilation leads lipopolysaccharide LPS lung lung inflammatory response Lungs mechanism mortality rates Non-invasive number Open-label oxygen parallel-group Pneumonia Pneumonitis Prophylactic Protein randomized clinical trial Randomized controlled trial Randomly receive reduce registry renal replacement therapy replacement therapy Respiratory failure SARS-CoV-2 severe COVID-19 patient severe COVID-19 patients Severity of disease Side effect single-center standard care Study protocol subcutaneously supplemental oxygen the cells Universal vasopressor support viral-induced virus
[DOI] 10.1186/s13063-021-05027-9 PMC 바로가기 [Article Type] Study Protocol

Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19)

입원한 COVID-19 환자의 중증 SARS-CoV-2 감염 예방을 위한 재조합 인간 C1 에스테라제 억제제(conestat alfa): 무작위, 병렬 그룹, 공개 라벨, 다중 센터에 대한 연구 프로토콜의 구조화된 요약 파일럿 시험(PROTECT-COVID-19)

Letter

Published on 2021-01-042022-09-10
Journal: Trials [Category] 임상,

[키워드] 24 hour 24 hours Activation activities acute lung injury addition adjusted Administered administration allergy Antibiotics anticipated anticoagulation arterial Arterial hypertension Basel Blinding BMI Brazil Breast Breast feeding breathing ambient air C-reactive protein C1 esterase inhibitor cardiovascular disease Caregivers changes in Chest Child-Pugh score chronic chronic pulmonary disease chronic renal disease cirrhosis class clinical Clinical improvement clinical trial comparator comparator Patients complement complement system completion conducted Conestat alfa Contact contact activation system contraindication control group Corticosteroids COVID-19 COVID-19 patient CT scan death defined discharge disease disease severity dissemination drug Duration Efficacy and safety element eligibility enrolment evidence of experimental arm family members FIVE followed by history hospital Hospitalization hospitalized patient hypertension ICU IL-6 inhibitor IL-6R improvement Incapacity include inclusion criteria individual Infection inflammatory cascade inflammatory cascades inflammatory proteins inhibitor Interactive Web Response System interim analysis Intravenous injection invasive invasive or non-invasive ventilation investigator-initiated investigators kallikrein kinin system laboratory parameter Liver cirrhosis Local Lung injury mechanical ventilation non-invasive ventilation not blinded number obesity objective Open-label open-label trial Ordinal Scale outcome outcome assessor outcome assessors oxygen oxygen saturation pandemic PaO parallel-group participant Participants Participation Patient performed Pregnancy primary endpoint progression proportion protocol pulmonary disease pulmonary involvement randomised randomization Randomized randomized trial receive recombinant recruited recruitment Registered Remdesivir renal renal disease required risk factor Sample size SARS-COV-2 infection SARS-CoV-2 pandemic scale screened secondary Secondary outcomes severe COVID-19 severe SARS-CoV-2 Standard of care status Study protocol subject supplemental oxygen supplementary material suspicion Switzerland Symptom the SARS-CoV-2 the WHO their family members Tocilizumab Treatment treatment arm Trial Two interim analyses Two interim analysis virological clearance website WHO WHO ordinal scale with COVID-19 X-ray
[DOI] 10.1186/s13063-020-04976-x PMC 바로가기 [Article Type] Letter

Treatment of COVID-19 With Conestat Alfa, a Regulator of the Complement, Contact Activation and Kallikrein-Kinin System

Immunology

Published on 2020-08-142022-11-01
Journal: Frontiers in Immunology [Category] COVID-19, MERS, SARS,

[키워드] Activation Administered Admission age ambient C-reactive protein C1 esterase inhibitor Case series Chest Clinical improvement complement complement system Computed tomography Concentration Conestat alfa Contact contact activation system Controlled clinical trial COVID-19 declined dose dysregulated immune response Efficacy elevated Evidence hyperinflammation Immediate Inflammation inflammatory cascade Inflammatory marker intervals Intravenous injection Kallikrein-kinin system Level lung involvement majority mechanical ventilation median Nasopharyngeal swab occurred oxygen saturation oxygen supplementation Patient patients potential benefit preventing disease progression progressive disease regulator required Safe SARS-CoV-2 severe coronavirus disease severe COVID-19 severe COVID-19 patients Severe COVID-19 pneumonia Switzerland System treated Treatment University Hospital Basel
[DOI] 10.3389/fimmu.2020.02072 PMC 바로가기 [Article Type] Immunology

C1 esterase inhibitor and the contact system in COVID-19

C1 에스테라제 억제제와 COVID-19의 접촉 시스템

Review

Published on 2020-08-012022-09-12
Journal: British Journal of Haematology [Category] MERS, SARS, 진단,